2016 Press Releases

2016 | 2015 | 2014
Keyword Search
11/22/16Depomed to Present at the Annual Piper Jaffray Healthcare ConferencePrinter Friendly Version
11/16/16Depomed Named to Deloitte's Technology Fast 500™ List of Fastest Growing Companies in North AmericaPrinter Friendly Version
11/07/16Depomed Reports Third Quarter 2016 Financial ResultsPrinter Friendly Version
11/04/16Depomed Announces New CAMBIA® FormulationPrinter Friendly Version
10/31/16Depomed to Report Third Quarter Fiscal Year 2016 Financial Results on Monday, November 7, 2016Printer Friendly Version
10/17/16Depomed and Starboard Announce Settlement AgreementPrinter Friendly Version
09/30/16Depomed Prevails in NUCYNTA Franchise ANDA Litigation Providing Market Exclusivity Until December 2025Printer Friendly Version
09/16/16Depomed Receives Request to Call Special Meeting of ShareholdersPrinter Friendly Version
09/08/16Data from Depomed’s Highly-Differentiated Pain and CNS-Focused Product Portfolio Presented at PAINWeek 2016Printer Friendly Version
09/07/16Depomed to Present at the Morgan Stanley Global Healthcare ConferencePrinter Friendly Version
09/06/16Depomed Announces Presentations at PAINWeek 2016Printer Friendly Version
08/03/16Depomed Reports Second Quarter 2016 Financial ResultsPrinter Friendly Version
07/27/16Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016Printer Friendly Version
07/18/16Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA PatentPrinter Friendly Version
07/07/16Depomed Releases Lazanda® 300 mcg Dose for Treatment of Breakthrough Cancer PainPrinter Friendly Version
07/06/16Depomed to Present at the Cantor Fitzgerald Healthcare ConferencePrinter Friendly Version
06/23/16Depomed Proposes to Call Special Meeting of Shareholders on October 28, 2016 Following Outcome of NUCYNTA Patent LitigationPrinter Friendly Version
06/14/16Depomed to Present at the JMP Securities Life Sciences ConferencePrinter Friendly Version
05/26/16Depomed Issues Statement in Response to Starboard’s Press ReleasePrinter Friendly Version
05/23/16Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory ProfilePrinter Friendly Version
05/18/16Depomed Announces District Court Order Extending Stay in NUCYNTA ANDA LitigationPrinter Friendly Version
05/16/16Depomed Announces Presentation of Cebranopadol Data at World Institute of Pain CongressPrinter Friendly Version
05/05/16Depomed Reports First Quarter 2016 Financial ResultsPrinter Friendly Version
05/03/16Depomed to Present at Healthcare Conferences in MayPrinter Friendly Version
04/28/16Depomed to Report First Quarter Fiscal Year 2016 Financial Results on Thursday, May 5, 2016Printer Friendly Version
04/25/16Depomed Announces Record Date to Determine Shareholders Entitled to Request Special MeetingPrinter Friendly Version
04/14/16Depomed Announces Decision Not To Pursue Proposed ReincorporationPrinter Friendly Version
04/08/16Depomed Issues Statement in Response to Starboard Value LP 13D FilingPrinter Friendly Version
04/04/16Depomed Announces Prepayment of $100 Million of Secured Debt FacilityPrinter Friendly Version
03/24/16Appeals Court Upholds Depomed Patents Asserted against Purdue PharmaPrinter Friendly Version
03/10/16Depomed to Host Analyst and Investor Day on Wednesday, March 23Printer Friendly Version
03/07/16Depomed to Present at 28th Annual ROTH ConferencePrinter Friendly Version
02/29/16Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All ArmsPrinter Friendly Version
02/22/16Depomed Reports Record Fourth Quarter and Full Year 2015 Financial ResultsPrinter Friendly Version
02/16/16Depomed to Report Fourth Quarter Fiscal Year 2015 Financial Results on Monday, February 22, 2016Printer Friendly Version
02/08/16Depomed Announces Favorable Markman Ruling in Nucynta® and Nucynta® ER Patent LitigationPrinter Friendly Version
02/03/16Depomed to Present at Healthcare Conferences in FebruaryPrinter Friendly Version
01/27/16Depomed Announces Save the Date for 2016 Analyst and Investor DayPrinter Friendly Version
01/04/16Depomed Announces Closing of Acquisition of U.S. Rights to Cebranopadol From GrunenthalPrinter Friendly Version

DEPO (Common Stock)

Change (%)
 + 0.14 (0.70%)
Market Cap

Data as of 12/08/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.